Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myeloma

Blood

Volumn 115, Issue 1, 2010, Pages 61-70

  Chen, Lijuan ^a,b   Wang, Siqing ^a,c   Zhou, Yiming ^a   Wu, Xiaosong ^a   Entin, Igor ^a   Epstein, Joshua ^a   Yaccoby, Shmuel ^a   Xiong, Wei ^a,c   Barlogie, Bart ^a   Shaughnessy Jr , John D ^a   Zhan, Fenghuang ^a,c  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b NANJING MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CASPASE; EARLY GROWTH RESPONSE FACTOR 1; SURVIVIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR JUN; UNCLASSIFIED DRUG; BIRC5 PROTEIN, HUMAN; BORONIC ACID DERIVATIVE; EGR1 PROTEIN, HUMAN; MICROTUBULE ASSOCIATED PROTEIN; PROTEIN C JUN; PYRAZINE DERIVATIVE;

APOPTOSIS; ARTICLE; CELL GROWTH; CELL SURVIVAL; COCULTURE; DOWN REGULATION; HUMAN; HUMAN CELL; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; MYELOMA CELL; OSTEOCLAST; PLASMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; CELL PROLIFERATION; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; MESENCHYMAL STEM CELL; METABOLISM; PATHOLOGY; PHENOTYPE; PROGNOSIS; PROTEIN BINDING; RISK FACTOR; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

APOPTOSIS; BORONIC ACIDS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOWN-REGULATION; EARLY GROWTH RESPONSE PROTEIN 1; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MESENCHYMAL STEM CELLS; MICROTUBULE-ASSOCIATED PROTEINS; MULTIPLE MYELOMA; OSTEOCLASTS; PHENOTYPE; PLASMA CELLS; PROGNOSIS; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-JUN; PYRAZINES; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 74949107707     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-03-210526     Document Type: Article

References (49)

1. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med. 2004;351:1860-1873.
2. Epstein J, Yaccoby S. Consequences of interactions between the bone marrow stroma and myeloma. Hematol J. 2003;4(5):310-314.
3. Mitsiades CS, Mitsiades NS, Munshi NC, Richardson PG, Anderson KC. The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions. Eur J Cancer. 2006;42(11):1564-1573.
4. Shaulian E, Karin M. AP-1 in cell proliferation and survival. Oncogene. 2001;20:2390-2400.
5. Zhang JY, Adams AE, Ridky TW, Tao S, Khavari PA. Tumor necrosis factor receptor 1/c-Jun-NH2-kinase signaling promotes human neoplasia. Cancer Res. 2007;67:3827-3834.
6. Lu A, Zhang F, Gupta A, Liu J. Blockade of AP1 transactivation abrogates the abnormal expression of breast cancer-specific gene 1 in breast cancer cells. J Biol Chem. 2002;277:31364-31372.
7. Bailey S, Hall AG, Pearson AD, Redfern CP. The role of AP-1 in glucocorticoid resistance in leukaemia. Leukemia. 2001;15:391-397.
8. Das M, Jiang F, Sluss HK, et al. Suppression of p53-dependent senescence by the JNK signal transduction pathway. Proc Natl Acad Sci U S A. 2007;104:15759-15764.
9. Angel P, Imagawa M, Chiu R, et al. Phorbol esterinducible genes contain a common cis element recognized by a TPA-modulated trans-acting factor. Cell. 1987;49:729-739.
10. Angel P, Hattori K, Smeal T, Karin M. The jun proto-oncogene is positively autoregulated by its product, Jun/AP-1. Cell. 1988;55:875-885.
11. Karin M. The regulation of AP-1 activity by mitogen-activated protein kinases. J Biol Chem. 1995;270:16483-16486.
12. Kolbus A, Herr I, Schreiber M, Debatin KM, Wagner EF, Angel P. c-Jun-dependent CD95-L expression is a rate-limiting step in the induction of apoptosis by alkylating agents. Mol Cell Biol. 2000;20:575-582.
13. Podar K, Raab MS, Tonon G, et al. Up-regulation of c-Jun inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myeloma. Cancer Res. 2007;67: 1680-1688.
14. Jia L, Yu W, Wang P, Li J, Sanders BG, Kline K. Critical roles for JNK, c-Jun, and Fas/FasLsignaling in vitamin E analog-induced apoptosis in human prostate cancer cells. Prostate. 2008; 68:427-441.
15. Colla S, Zhan F, Xiong W, et al. The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cells. Blood. 2007;109:4470-4477.
16. Hideshima T, Mitsiades C, Akiyama M, et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood. 2003;101:1530-1534.
17. Kajiguchi T, Yamamoto K, Iida S, Ueda R, Emi N, Naoe T. Sustained activation of c-jun-N-terminal kinase plays a critical role in arsenic trioxide-induced cell apoptosis in multiple myeloma cell lines. Cancer Sci. 2006;97:540-545.
18. Thiel G, Cibelli G. Regulation of life and death by the zinc finger transcription factor Egr-1. J Cell Physiol. 2002;193:287-292.
19. Harada T, Morooka T, Ogawa S, Nishida E. ERK induces p35, a neuron-specific activator of Cdk5, through induction of Egr1. Nat Cell Biol. 2001;3: 453-459.
20. Sukhatme VP, Cao XM, Chang LC, et al. A zinc finger-encoding gene coregulated with c-fos during growth and differentiation, and after cellular depolarization. Cell. 1988;53:37-43.
21. Kaufmann K, Thiel G. Epidermal growth factor and platelet-derived growth factor induce expression of Egr-1, a zinc finger transcription factor, in human malignant glioma cells. J Neurol Sci. 2001;189:83-91.
22. Kaufmann K, Thiel G. Epidermal growth factor and thrombin induced proliferation of immortalized human keratinocytes is coupled to the synthesis of Egr-1, a zinc finger transcriptional regulator. J Cell Biochem. 2002;85:381-391.
23. Liu C, Rangnekar VM, Adamson E, Mercola D. Suppression of growth and transformation and induction of apoptosis by EGR-1. Cancer Gene Ther. 1998;5:3-28.
24. Nair P, Muthukkumar S, Sells SF, Han SS, Sukhatme VP, Rangnekar VM. Early growth response-1-dependent apoptosis is mediated by p53. J Biol Chem. 1997;272:20131-20138.
25. Virolle T, Adamson ED, Baron V, et al. The Egr-1 transcription factor directly activates PTEN during irradiation-induced signalling. Nat Cell Biol. 2001; 3:1124-1128.
26. Levkovitz Y, Baraban JM. A dominant negative inhibitor of the Egr family of transcription regulatory factors suppresses cerebellar granule cell apoptosis by blocking c-Jun activation. J Neurosci. 2001;21:5893-5901.
27. Levkovitz Y, O'Donovan KJ, Baraban JM. Blockade of NGF-induced neurite outgrowth by a dominant-negative inhibitor of the egr family of transcription regulatory factors. J Neurosci. 2001; 21:45-52.
28. Hoffmann E, Ashouri J, Wolter S, et al. Transcriptional regulation of EGR-1 by the interleukin-1-JNK-MKK7-c-Jun pathway. J Biol Chem. 2008; 283:12120-12128.
29. Gibbs JD, Liebermann DA, Hoffman B. Leukemia suppressor function of Egr-1 is dependent on transforming oncogene. Leukemia. 2008;22: 1909-1916.
30. Gibbs JD, Liebermann DA, Hoffman B. Egr-1 abrogates the E2F-1 block in terminal myeloid differentiation and suppresses leukemia. Oncogene. 2008;27:98-106.
31. Lucerna M, Pomyje J, Mechtcheriakova D, et al. Sustained expression of early growth response protein-1 blocks angiogenesis and tumor growth. Cancer Res. 2006;66:6708-6713.
32. Ronski K, Sanders M, Burleson JA, Moyo V, Benn P, Fang M. Early growth response gene 1 (EGR1) is deleted in estrogen receptor-negative human breast carcinoma. Cancer. 2005; 104:925-930.
33. Barlogie B, Anaissie E, van Rhee F, et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol. 2007;138:176-185.
34. Shaughnessy JD Jr, Haessler J, van Rhee F, et al. Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics. Br J Haematol. 2007;137:530-536.
35. Barlogie B, Anaissie E, van Rhee F, et al. The Arkansas approach to therapy of patients with multiple myeloma. Best Pract Res Clin Haematol. 2007;20:761-781.
36. Barlogie B, Haessler J, Pineda-Roman M, et al. Completion of pre-maintenance phases in total therapies 2 and 3 improves clinical outcomes in multiple myeloma - an important variable to be considered in clinical trial designs. Cancer. 2008; 112:2720-2725.
37. Yaccoby S, Wezeman MJ, Henderson A, et al. Cancer and the microenvironment: myeloma-osteoclast interactions as a model. Cancer Res. 2004;64:2016-2023.
38. Zhan F, Huang Y, Colla S, et al. The molecular classification of multiple myeloma. Blood. 2006; 108:2020-2028.
39. Shaughnessy JD Jr, Zhan F, Burington BE, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007;109:2276-2284.
40. Ahmed MM. Regulation of radiation-induced apoptosis by early growth response-1 gene in solid tumors. Curr Cancer Drug Targets. 2004; 4:43-52.
41. Xiong W, Wu X, Starnes S, et al. An analysis of the clinical and biological significance of TP53 loss and the identification of potential novel transcriptional targets of TP53 in multiple myeloma. Blood. 2008;112:4235-4246.
42. Hyun T, Yam A, Pece S, et al. Loss of PTEN expression leading to high Akt activation in human multiple myelomas. Blood. 2000;96:3560-3568.
43. Hurt EM, Thomas SB, Peng B, Farrar WL. Reversal of p53 epigenetic silencing in multiple myeloma permits apoptosis by a p53 activator. Cancer Biol Ther. 2006;5:1154-1160.
44. Wagner M, Schmelz K, Dorken B, Tamm I. Transcriptional regulation of human survivin by early growth response (Egr)-1 transcription factor. Int J Cancer. 2008;122:1278-1287.
45. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997;3:917-921.
46. Yu J, Leung WK, Ebert MP, et al. Increased expression of survivin in gastric cancer patients and in first degree relatives. Br J Cancer. 2002;87:91-97.
47. Satoh K, Kaneko K, Hirota M, Masamune A, Satoh A, Shimosegawa T. Expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumors. Cancer. 2001;92: 271-278.
48. Yamamoto H, Ngan CY, Monden M. Cancer cells survive with survivin. Cancer Sci. 2008;99:1709-1714.
49. Shin S, Sung BJ, Cho YS, et al. An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry. 2001;40:1117-1123.